QUICK LINKS
MAIN MENU
CONNECT WITH US

Clinical Trial Details

Title
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome –the AEGIS-II Study
Study Description

The purpose of this study is to find out how effective and safe CSL112 is at reducing the risk of dying from heart related events, having another heart attack, or having a stroke.

If you agree to join the study, screening tests will be performed while you are in the hospital to assess your eligibility for the study. If you are eligible to take part in the study, you will be randomized to receive either the study drug or placebo. “Randomized” means that you will be assigned by chance, like flipping a coin, to take the study drug (CSL112) or the placebo. You will have a 50/50 chance of receiving either CSL112 or placebo.

Investigators

Principal Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC
Medicine

Resources

News & Announcements

Upcoming Events

Jun 2

The Anatomy of Abstracts and Manuscripts

From 12:00 PM until 1:00 PM